Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension (HYPER2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03810443 |
Recruitment Status :
Not yet recruiting
First Posted : January 18, 2019
Last Update Posted : January 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pulmonary Arterial Hypertension | Diagnostic Test: Hyperventilation test | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension |
Estimated Study Start Date : | January 14, 2019 |
Estimated Primary Completion Date : | July 14, 2021 |
Estimated Study Completion Date : | July 14, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: pulmonary arterial hypertension
The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
|
Diagnostic Test: Hyperventilation test
The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
Other Names:
|
- Prevalence of the hyperventilation syndrome [ Time Frame: 18 months ]Prevalence of the hyperventilation syndrome in a population with pulmonary arterial hypertension
- anxiety-depression questionary score [ Time Frame: 18 months ]results of anxiety-depression questionary
- dyspnea score [ Time Frame: 18 months ]results of dyspnea questionary
- quality of life score [ Time Frame: 18 months ]results of quality of life questionary

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Non smoker or tobacco stopped for minimum 2 years ans maximum 10 year-pack. - Idiopathic, heritable, related to drug or toxics, associated with controlled pulmonary hypertension. Diagnosis and treatment of pulmonary hypertension for more than 4 months.
- Optimal control of pulmonary hypertension (no right heart failure symptom and NTproBNP < 300ng/L or Brain Natriuretic Peptide(BNP) < 50 ng/L and optimal hemodynamic results measured by a right heart catheterization in the last year: right atrial pressure < 8 mmHg, cardiac index > 2,5 L/min/m2, veinous saturation in oxygen > 65%)
- Informed and written consent
- Non-affiliation to a social security
Exclusion Criteria:
- Existence of another form of pulmonary hypertension
- Existence of vocal cord dysfunction
- Pregnancy
- Obesity> stage 2 (BMI 35 kg / m2)
- Age ≥ 75 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03810443
Contact: Etienne-Marie JUTANT, CCA | 01 45 21 78 91 | etiennemarie.jutant@aphp.fr |
France | |
Hôpital Bicêtre - Pneumology department | |
Le Kremlin-Bicêtre, France, 94270 | |
Contact: Etienne-Marie JUTANT, CCA 01 45 21 78 91 etiennemarie.jutant@aphp.fr |
Principal Investigator: | Etienne-Marie JUTANT, CCA | APHP |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT03810443 |
Other Study ID Numbers: |
APHP180352 |
First Posted: | January 18, 2019 Key Record Dates |
Last Update Posted: | January 18, 2019 |
Last Verified: | December 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hyperventilation |
Familial Primary Pulmonary Hypertension Hyperventilation Hypertension Vascular Diseases Cardiovascular Diseases |
Hypertension, Pulmonary Lung Diseases Respiratory Tract Diseases Respiration Disorders Signs and Symptoms, Respiratory |